Chinese Journal of Cancer
Chinese Journal of Cancer (the Chinese title being 《癌症》 and commonly abbreviated as Chin. J. Cancer.) is an open access oncology journal sponsored by the Sun Yat-sen University Cancer Center. Founded in 1982, it has been published under the title Cancer Communications since 2018, and its 2025 impact factor stands at 28.4.Chinese Journal of Cancer（中文名《癌症》，常用缩写 Chin. J. Cancer.）是中山大学肿瘤防治中心主办的肿瘤学开放获取期刊，1982 年创刊，2018 年起刊名更替为 Cancer Communications，2025 年影响因子为 28.4。[1]
Scope
- Scope: the journal covers all areas of cancer research, spanning basic studies, clinical trials and translational medicine, and offers a high-visibility forum for an international readership.学科定位： 期刊面向全部癌症研究领域，覆盖基础研究、临床试验与转化医学，为国际读者群提供高可见度的交流平台。
- Article types: it carries original research, reviews, extra views, perspectives, supplements and spotlights.稿件类型： 刊载原创研究论文、综述、「Extra Views」、「Perspectives」、增刊与「Spotlight」一类稿件。
- Publication criteria: the primary criteria are originality, outstanding scientific merit and general interest. The editorial board draws its members from around the world and strives to maintain the highest standards of excellence.发表标准： 录用与否首先看原创性、突出的科学价值与普遍兴趣三点，编委会由世界各地成员组成，力求保持最高水准。
- Indexing and open access: the journal publishes on an open access basis and is indexed in some twenty databases including SCI and PubMed.收录与开放获取： 期刊以开放获取方式出版，被 SCI、PubMed 等二十余个数据库收录。
- Metrics: the 2025 impact factor is 28.4, ranking 11th of 333 oncology journals in the first quartile, a position within the top 3.2% of the category.收录与指标： 2025 年影响因子为 28.4，在肿瘤学类别 333 种期刊中列第 11 位（Q1 区），居前 3.2%。[2]
History
- Founded in 1982: the journal began in 1982 under the Chinese title 《癌症》, sponsored by the Sun Yat-sen University Cancer Center.1982年创刊： 期刊于 1982 年以中文刊《癌症》创刊，由中山大学肿瘤防治中心主办。
- Title changes: bilingual publication began in 2008, the journal turned fully English in 2010 under the title Chinese Journal of Cancer, and in 2018 it was renamed Cancer Communications.刊名沿革： 2008 年实行中英双语出版，2010 年起转为全英文出版并启用英文刊名 Chinese Journal of Cancer，2018 年再度更名为 Cancer Communications。
- Publisher history: the journal was co-published with BioMed Central until the end of 2019, moved to Wiley in 2020, and joined the Science partner journal programme in 2026 with the American Association for the Advancement of Science as its publisher.出版方沿革： 期刊曾与 BioMed Central 合作出版，2019 年 12 月底结束该合作，2020 年起转由 Wiley 出版，2026 年起加入 Science 合作期刊体系，由美国科学促进会承担出版。[3]
- Impact milestones: the impact factor reached 5.627 in 2019, crossing 5 for the first time and entering the first quartile of oncology, and climbed to a record 28.4 in 2025.影响因子节点： 2019 年影响因子达 5.627，首次突破 5 分并进入肿瘤学 Q1 区；2025 年升至 28.4，创历史新高。
- Recognition: the journal is listed in the China Association for Science and Technology T1 grading for oncology and was named in the 2025 directory of world-class sci-tech journals.学会认可： 期刊入选中国科协肿瘤学 T1 分级目录，并入选 2025 年度世界一流科技期刊目录。
- Frequency: the journal appears monthly, with twelve issues a year.刊期： 期刊为月刊，每年出版 12 期。[4]
Editors
- Editor-in-chief: the journal is led by academician Rui-Hua Xu of the Sun Yat-sen University Cancer Center, working with an international editorial board.现任主编： 主编为徐瑞华院士，任职于中山大学肿瘤防治中心，带领一支国际编委会。
- Honorary editor: academician Yi-Xin Zeng serves as honorary editor-in-chief.名誉主编： 曾益新院士列名为名誉主编。
- Editorial board: the board is composed of members from around the world, covering directions from basic cancer research to clinical translation.编委构成： 编委会由世界各地成员组成，覆盖癌症基础研究与临床转化等方向。
- Submission and peer review: manuscripts are lodged through an online submission system and undergo peer review, with originality, scientific merit and general interest as the leading criteria.投稿与评审： 稿件经在线投稿系统递交并接受同行评审，取舍以原创性、科学价值与普遍兴趣为首要标准。[5]
- Editorial policy: the journal positions itself as a high-impact bridge for global cancer research, reporting on directions from epidemiology and pathogenesis to diagnosis and therapy.编辑方针： 期刊定位于连接全球癌症研究的高影响力平台，报道涵盖流行病学、发病机制、诊断、治疗等方向。